Introduction to Bioregulatory Medicine

Thieme Verlag Sommer-Druck Smit, Introduction to WN 025912/01/01 11.8.2009 Frau Kurz Feuchtwangen Bioregulatory Medicine TN 147611 Index

161

Index

A anaerobiosis theory 129 Arndt-Schulz rule 21–22, 113 anergy, Acidum alpha-ketoglutari- Arnica montana 21–22, 74 acetoacetate 98 cum 89 arthritis 157 acetone 98, 99 anthraquinones 108, 117–118, association-induction theory acetyl coenzyme A 84, 85, 97, 98, 121 134–135 99 antibodies, antigen-specific ATP synthetase 106 oxaloacetate metabolism 26–27 autoimmune diseases 156 101–102 antigen presenting cells (APCs) autologous blood therapies 148, Acidum alpha-ketoglutaricum 23, 25, 70–71 155 88–90 antigens 25, 26 autoregulating systems (ARSs) Acidum cis-aconitum 87–88 antihomotoxic medications 45, 2–12, 13 Acidum citricum 83–87 46–47 base rigidity 9, 10 Acidum fumaricum 92–94 availability 145 bipolar feedback systems 4, 6, Acidum succinicum 90–91 classification 142–143 11, 12, 13, 27 acne 158 dosage 146–147 blood glucose regulation 12, aconitase reaction 88 functiotropic 142–143 13 cis-aconitic acid 87–88 multitargeted interven- blood pressure 12 adaptive immune system 70–73 tions 76–77 body temperature 9–12 adenosine diphosphate (ADP) names 145 closed systems 7 105, 106 organotropic 142–143 cybernetics 4–6 adenosine triphosphate (ATP) potencies 146, 147 definition 2 105, 106, 109–110, 112 quinones 113 fluctuating reality 3 adrenal glands, parabenzoquinone selection 145–147 homeostasis 2, 3–4 affinity 119 tolerability 70 homotoxins 35 adrenaline 54 antihomotoxic treatment immune system 69–70 adrenocorticotropic hormone biopuncture 149–154 inflammation 19–24 (ACTH) 27, 28, 29 catalysts 78, 79–98, 99, interactive 1 aging 100–105 negative feedback systems 4–5 Baryum oxalsuccinicum 92 cell support 78–98, 99, open systems 7 oxidative phosphorylation 100–131 positive feedback systems 4, slowing 111 detoxification 49–69 5–6 agricultural chemicals 52–53, 58 drainage 49–69 rigid 20, 73 alarm stage of stress 30 injection therapies 147–154 set points 3 albumin 31 organ support 131–143 stress-related exhaustion alcohol dehydrogenase pathway oxidative phosphorylation 29–31 58, 59 105–131 top rigidity 8, 9 aldehydes 126–128 planning 146 wave pattern within set point aldosterone 12 special methods 147–154 margins 7–8 allergies, progressive auto-sanguis antioxidants 106 therapy 156 apoptosis 141 Amadori reaction 128 arginine 100–101 amino acids 98, 100 Arndt, Rudolf 21

aus: Smit u.a., Introduction to Bioregulatory Medicine (ISBN 9783131476111) © 2009 Georg Thieme Verlag KG Thieme Verlag Sommer-Druck Smit, Introduction to WN 025912/01/01 11.8.2009 Frau Kurz Feuchtwangen Bioregulatory Medicine TN 147611 Index

162 Index

B general excretion infusion cybernetics 4–6 156 cyclo-oxygenase (COX) pathway B-cells 70 Krebs cycle intermediates 78, 20–21 bacteria, symbiotic gut 66–67, 79–80, 104 cyclo-oxygenase 2 (COX-2) inhibi- 76 CD markers 70 tors 21 barium 91–92 CD4+ T-cells 26, 70, 71 cytochrome c oxidase 106 Baryum oxalsuccinicum 91–92 CD8+ T-cells 26, 70 cytochrome c reductase 106 basic combinations 143 cell(s) cytochrome P450 (CYP450) system Bellis perennis 74 cytoskeleton 135 58–59, 67 Berberis-Homaccord 153 embedded 140 cytogenetics 138 Bernard, Claude 3, 4, 131–132 function 3, 4 cytokines 16, 19–20, 73 beta-oxidative path 84, 85 health 140–142 cytoplasm 138 Bier, August 139 interdependence 136 bile 31, 62 matrix 135 bilirubin 32 nonembedded 140 D biopuncture 149–154 nucleus 135, 138 clinical effects 152 permeability 134 defense mechanisms 36 contraindications 154 respiration 111, 111 degenerative joint diseases 156 definition 149 cell concept, new 133–135 dendritic cells 25–26 injection 149–151 cell death 141 desoxycortisol, diurnal techniques 152–154 cell paradigm 137–139 rhythm 29 medications 150 cell support 78–98, 99, 100–131 detoxification 49–69, 146 technical complications 154 cellular phases of disease evolu- “4-S” treatment 68–69 bioregulation, definition 1 tion 38–39, 40–41 liver 159 bipolar feedback systems 4, 6 chemiosmotic mechanism 106 organs 61–69 blood glucose homeostasis 12, chemokines 19 physiology 54, 56–61 13 children, Coenzyme compositum diabetes 83, 96, 97 hypophysis 27 actions 104 dicarbonyl groups 130 thermoregulation 11 cholestasis 159 diets bisphenol A 53 cholesterol 31, 84, 85 carbohydrate-rich 98, 99 blood pressure 12 chondrocytes 14 low-fat 100, 101 blood therapies, autologous 148, chromatin 138 slimming and pyruvate 155 chromosomes 138, 139 use 81–82 blood–brain barrier 58 circulatory disorders 157 disease Bürgi, Emil 46 citric acid 83–87, 97 cell function 3, 4 Bürgi principle 46–47 citric acid cycle see Krebs cycle expression 36 cleansing therapy 146 homotoxicological definition cloning 65 35–36 C closed systems 1, 7 treatment at organ level 141 Coenzyme compositum 103–104 disease evolution 42–43 Calendula officinalis 22 coenzyme Q see ubiquinone cellular phases 38–39, 40–41 cancer, etiopathogenesis colitis 159 dedifferentiation phase 38–39, 112–113, 129 colloids 136 41, 42 Candida albicans 72–73 complement 74 degeneration phase 38–39, Cannon, Walter Bradford 3, 4, complementary medicine, extra- 40–41, 42 132 cellular matrix 16 deposition phase 38–39, 40, carbon dioxide emissions 6 composita 142 42 carbonyl compounds 126, 127 conception, failure 160 disordered progression 43 carbonyl groups 130 connective tissue 136–137 excretion phase 37, 38–39, 42 Cassia 108 corticotrophin-releasing hormone humoral phases 37, 38–39 catalase 67 (CRH) 27, 28 impregnation phase 38–39, catalyst preparation groups cortisol 4–5, 7, 28, 29, 64 40, 42 (CPGs) 46 cortisone 64–65, 76 inflammation phase 37, catalysts 78, 79–98, 99, Crick, Francis 139 38–39, 42 100–105, 142 crystallography 138–139 linear progression 43

Index 163

matrix phases 38–39, 40 F Glyoxal compositum 130 phases 37, 38–39, 40–41 glyoxalase system 127, 128, 129 – regulation/compensation divi- FADH2 106, 109 glyoxalation process 125 128 sion 38–39, 41, 42, 142, 143 fast acetylators 59 glyoxylide 115 disease evolution table (DET) fasting 101 greater defense system 24–33 36–37, 38–39, 40–43, 142 fatigue 95 detoxification in liver 31–33 classification 38–39, 41–42 fats, accumulation 98, 99 neural reflex system 31 therapy schemes 42 feedback systems 1 reticuloendothelial system diurnal rhythm, ACTH 29 feed-forward systems 7 24–27 DNA 138–139 fetus, toxin exposure 58 see also hypothalamus–hypo- dose–response curves 51 fibroblasts 18, 19 physis–suprarenal cortex double helix model 139 fibromyalgia 95, 96 Grifola frondosa (maitake) 128 drainage 49–69 Fishbein, Morris 115 Gripp-Heel 148, 154 Drosera 118 flavin-adenine dinucleotide ground regulation system 14–19, drugs, therapeutic 53 (FAD) 90–91 136–137 drugs of abuse 53 flavin-containing mono-oxidases ground substance 14, 15 (FMOs) 58 gut-associated lymphoid tissue Flemming, Walther 138 (GALT) 74, 76 E fluctuating reality 3 fluid interchange 65–66 Echinacea compositum 148 food additives/preservatives H eczema 158 53–54 elderly people free radical(s) 107, 111, 111 Hahnemann, Samuel 160 Coenzyme compositum free radical scavengers 67 hair 68 actions 103–104 fructosamine 128 health 2 diabetes 96 fumaric acid 92–94 evolution 43 heart disease 158 functiotropic medications heart disease 158 elimination, organs 61–69 142–143 heart rhythm 3 Embden–Meyerhof cycle 112, heartburn 159 128 heavy metals 52, 68 embryogenesis 128, 140 G Helicobacter pylori 159 Engystol 23–24, 74, 76, 77, 148, helminths 72 154 gallbladder 62 hematogenic oxygenation therapy enterohepatic circulation 62 gastrointestinal tract 67, 159 155 environmental toxins 50, 51 gastrulation 140 heme 90, 92 eosinophilic rhinosinusitis 73 general adaptation syndrome Henderson, Lawrence 132 epigenetics 51 (GAS) 29–30 Hepar compositum 153 Euphorbium compositum 148, general excretion infusion 156 hepatic steatosis 83 154 genetic mutations 113 hepatitis 158 excretion infusion 158, 159 genetics 138 hepatocarcinogenesis 92, 93 exhaustion 30, 89 global warming 6 hepatocytes 31, 61–62 extracellular matrix (ECM) 14–19 gluconeogenesis 95, 97, 98, 100 Hepeel 143, 153 cellular health 140–142 glucose histamine 54, 67 detoxification 17, 64–65 blood level regulation 12, 13 homaccords 143, 147 elimination 64–65 liver storage 31, 32 homeopathic substances 74, 76 homeodynamics of fluids glutamic acid 88–90 homeosiniatry 148–149 132–133 glutathione 67 homeostasis 1, 2, 3–4 organ support 131–132, glycation, advanced 123 blood glucose 12, 13 135–137 glycation end products, advanced deregulation by toxins 17–18 terrain concept 131–132 123, 125, 128 inflammation goal 19, 21 transport pathway role 137 glycoaldehyde 126–127, 128 liver function 31 glycogen 32 homing 65 glycolysis 106 homotoxicology glycosaminoglycans 14, 17, 18, 64 applied 73–74, 75, 76 glyoxal 122–125, 129, 130 case histories 146

164 Index

catalysts 78, 79–98, 99, infections, liver role 32–33 kidneys 62–63 100–105 inflammation Koch, William F. 114–115, 132 organ support 131–143 biological objectives 19 Kopaczwewski, Waldislaw 132, oxidative phosphorylation cytokines 19–20 133 105–131 disease evolution phase 37, Krebs, Hans Adolf 46, 78 change therapy 106–107, 38–39, 42 Krebs cycle 7, 46, 78, 84 121–122 down-regulation 45–46 alternative catabolic pathway quinones 114 extracellular matrix 15–16 125, 126 therapy of Krebs cycle homeostasis 19, 21 defective functioning 114 changes 103–104 turbocleansing process 18–19 homotoxicological therapy of see also antihomotoxic medica- inflammation-regulating drugs changes 103–104 tions; antihomotoxic treatment (IRDs) 22–24 intermediate products 78–80 homotoxins 35, 74 inflammatory joint diseases 157 oxaloacetate 98, 100, 101, 103 homotoxone 115 infusion therapy 149 Hooke, Robert 137 arterial circulation disorders Hormeel 153, 160 157 L human leukocyte antigens (HLA) cholestasis 159 class II 23, 26, 71 degenerative joint diseases 156 large granular lymphocytes (LGLs) hyaluronic acid 14, 17, 64 heartburn 159 70 hydrolases 58, 59 Helicobacter pylori 159 Larsen, Soren 6 hydroquinone 115–116 hepatitis 158 Larsen effect 6 beta-hydroxybutyrate 98, 99 hyperacidity 159 Liebig, Justus von 107 hyperacidity 159 inflammatory joint diseases 157 ligament infiltration 153 Hypericum 108 liver detoxification 159 lipid metabolism, pyruvate 82 hyperthyroidism 121 renal excretion 160 lipoic acid 106 Hypophysis suis 160 senile heart 158 lipoproteins 57 hyporeactivity, Acidum alpha- stenocardia 158 liver ketoglutaricum 89 venous circulation disorders detoxification 31–33, 61–62, hypothalamus 11, 29 157 159 hypothalamus–hypophysis– vertigo 157 elimination 61–62 suprarenal cortex 4–5, 27–31 injection therapies 147–154 function 32 hypothyroidism 65, 121–122 techniques 152–154 homeostasis 31 Injeels 147 infection fighting 32–33 insulin secretion 90 liver disease 158–159 I interferon(s) 19 locomotor system diseases interferon gamma (IFN-gamma) 156–157 immune cascade 65 8, 23–24 locus minoris resistentia 141 immune reactions, neural reflex interleukin(s) (ILs) 19 lungs 66 system 31 interleukin 10 (IL-10) 8 lymph system 65–66 immune rigidity 73–74, 75, 76 internal environment 1 lymphoid organs 25 immune system intramuscular injections 153 Lymphomyosot 74, 76, 153, 154, adaptive 70–73 iron-sulfur clusters 87 155 autoregulatory system 69–70 lymphoreticular system complexity 76–77 see reticuloendothelial system lymph nodes 65 J immunoglobulins 25, 26–27 immunological bystander reac- Juglans 118 M tion 74, 75 immunomodulation 69–74, 75, macrophage system 32–33 76–77 K maitake 128 applied homotoxicology major histocompatibility complex 73–74, 75, 76 alpha-ketoglutaric acid 88–90 (MHC) class II 23, 26, 71 multitargeted interventions ketone bodies 98, 100 malate 97 76 ketonemia 98 malic acid 95–97 immunomodulators 76 ketones 126, 127 malonide 115

Index 165

Materia Medica 45 O phagocytosis 18–19, 22 matrix phases of disease evolution phosphate, inorganic (Pi) 105 38–39, 40 ointment dressings 147 phthalates 53 membrane-pump theory of open systems 1, 7 phytohomeopathics 146 cell 133–134 oral tolerance 45 Pischinger, Alfred 14, 131, Mendel, Gregor 138 organ extracts 142 136–137 messenger RNA 139 organ perfusion 57 plant preparation groups (PPGs) metalloproteinases 16 organ preparation groups 45–46 45 metals 52, 68 organ regulation 139–140 plasticizers 53 methylglyoxal 126–127, 128, organ regulators 142 pollutants 52, 108, 123 129, 130 organ support 131–143 polybrominated biphenyl ethers mevalonate 90, 91 cell concepts 133–135 (PBBs) 53 milk, toxin excretion 68 extracellular matrix 131–132, polychlorinated biphenyls mineral preparation groups 45 135–137 (PCBs) 58 mitochondria 106, 107–111 matrix fluids 132–133 positive feedback systems 4, mitochondrial therapy 103 practical organ regulation 5–6 mitosis 138 139–140 potency chords 147 mononuclear phagocyte system regulative mechanisms 135 pressure point 148 see reticuloendothelial system organochlorine pesticides 53, pressure receptors 12 Morgan, Thomas 138 58, 68 progressive auto-sanguis therapy motif formation 74 organoregulators 141 148, 155 mucosa-associated lymphoid organotropic medications acne 158 tissue (MALT) 66 142–143 allergies 156 mucosal distress syndrome 76 organs, weakest 141 arthritis 157 mucosal membranes 66–67 osmoregulation 5 colitis 159 multiple chemical sensitivity 50 osteoarthritis 157 eczema 158 muscle agonist/antagonist 8 osteoblasts 14 failure to conceive 160 muscle protein catabolism 95 osteoporosis 85 Helicobacter pylori 159 myocardium 97 Ovarium compositum 153 osteoarthritis 157 oxalacetic acid 97–98, 99, recurring urinary tract infec- 100–103 tion 160 N oxidative phosphorylation Promine 129, 130 105–131 prostaglandin synthesis inhibition NADH 105–106, 109 homotoxicological therapy of 20 NADH dehydrogenase 106 changes 106–107, 121–122 prostate carcinoma 84 naphthoquinone 107, 111, 118, oxidative stress, pollutants 108 protein binding 57 119 oxygen proteoglycans 14, 17, 18, 64 hypothyroidism 121–122 scarcity in carcinogenesis 113, protons 109–111, 110 Natrium oxalaceticum 83, 129 protoplasm 134 97–98, 99, 100–103 tissue supply 96–97 psoriasis, Acidum fumaricum Natrium pyruvicum 80–83 ozone autologous blood therapy 92–93, 94 natural killer (NK) cells 26 155 psycho-neuro-endocrine immu- necrosis 141 nology (PNEI) 28, 30 negative feedback systems 4–5 psychosomatism/psychosomatic neoplastic cells 112, 113, 129 P disorders 30–31 nephron 63 psychotoxins 54 nerve excitation 31 pancreas, blood glucose homeo- pyruvic acid 80–83 nervous hyperexcitability, stasis 12, 13 Acidium cis-aconitum 87, 88 parabenzoquinone 106, 113, neural reflex system 31 115, 118–120 Q neutrophils, antitumor activity parasites 72 128 parathyroidectomy 114 quinhydrone 116–117 nitric oxide 100–101 Pasteur, Louis 132 quinones 115–121 non-steroidal anti-inflammatory pesticides 52–53, 58 characteristics 107–112 drugs (NSAIDs) 20–21 phagocytes 126, 128 clinical medicine 113

166 Index

oxidative phosphorylation subcutaneous injections 152–153 slow-exchange system 60, 61 change therapy 106–107 succinate dehydrogenase 106 storage 57–58 redox potential 107–112, 114 succinic acid 90–91, 97 susceptibility 50 suis-organ Injeels 142 tissue affinity 57–58 superoxide dismutase 67 tolerance 50 R suprachiasmatic nucleus 29 transport 56–57 sweat 67, 68 transforming growth factor beta Reckeweg, Hans-Heinrich 78–79, Szent-Gyorgyi, Albert 128–130 (TGF-beta) 23, 46, 77 114–115, 130, 139 Traumeel 23, 74, 76, 77, 153 – regulation disturbances, treat- Treg-cells 45 46, 71, 74 ment 147 T tricarboxylic acid (TCA) cycle regulation/compensation division see Krebs cycle (RCD) 38–39, 41, 42, 142, 143 T-lymphocytes 70 triquinoyl 120 regulative mechanisms 135 see also CD4+ T-cells; CD8+ tuberculosis vaccine 74 renal excretion 160 T-cells; TH helper T-cells renal insufficiency, chronic 124 T-dependent antigens 26 renin–angiotensin system 12 temperature, body 9–12 U respiration rate 3 tendon injections 153 respiratory chain, ubiquinone terrain concept 131–132 Ubichinon compositum 113 – – 112 113 TH0 helper T-cells 71, 76 ubiquinone 108, 111, 120 121 – – respiratory diseases 154 155 TH1 helper T-cells 8, 23, 46, 71, respiratory chain 112 113 reticuloendothelial system 74 Ubiquinone compositum 107, – 24 27 switch to TH2 76 122 – Retine 128, 129, 130 TH2 balance 72 73 urea cycle 100, 103 – rickets, Acidum citricum Injeel TH2 helper T-cells 8, 23, 46, 71, urinary tract infection, recurring 85 74 160

Rokitansky, Carl 3 switch to TH1 76 urogenital diseases 160 – TH1 balance 72 73 Uva ÿuinin 115 TH17 helper T-cells 71 UV-irradiated autologous blood S thermoregulation 10–12 therapy 155 thromboxane pathway 21 “4-S” treatment 68–69 thyroid hormone, ECM regulation saliva, toxin excretion 68 64 V Schade, Heinrich 135–136 T-independent antigens 26 Schiff bases 126, 127, 128 tissues vascular diseases 157 Schleiden, Matthias 137 acidosis 103 vertigo 157 Schulz, Hugo Paul Friedrich 21 embryonic differentiation 37, Vertigoheel 157 Schwann, Theodor 137, 138 38–39 Virchow, Rudolf 3, 64, 138 Selye, Hans 27, 28, 29–30, toxicity measurement 51 vitamin B 106 132–133 toxicodynamics 54 vitamin K 108, 118, 119 set point objective 3, 7–8, 9, 10 toxicokinetics 54, 56 Vlès, Fred 133 sick building syndrome (SBS) 50 toxins Vries, Hugo De 138 skin 67–68 absorption 56, 67 diseases 157–158 classes 51–54, 55 Solidago compositum 153 distribution 57–58 W sorption theory of cells 134 drainage 97 Starling, Ernest 132 effects 50–51 Watson, James 139 stenocardia 158 elimination 59–60 wave pattern, within set point stress 29–31 endogenous 49, 54 margins 7–8 cortisol disruption 64 environmental 50, 51 wood preservatives 52–53 hypothalamus–hypophysis– exogenous 49 suprarenal cortex 28 fetal exposure 58 psychosomatic disorders 31 metabolism 58–59 stages 30 rapid-exchange system 60